506 related articles for article (PubMed ID: 19368953)
21. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
22. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma.
Takeuchi T; Ohishi Y; Imamura H; Aman M; Shida K; Kobayashi H; Kato K; Oda Y
Am J Surg Pathol; 2013 Jul; 37(7):1091-9. PubMed ID: 23681072
[TBL] [Abstract][Full Text] [Related]
23. [Diagnostic difficulties in serous "borderline" tumors of the ovary].
Vereczkey I; Tóth E; Orosz Z
Magy Onkol; 2009 Mar; 53(1):23-31. PubMed ID: 19318323
[TBL] [Abstract][Full Text] [Related]
24. Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features.
Ramalingam P; Middleton LP; Tamboli P; Troncoso P; Silva EG; Ayala AG
Ann Diagn Pathol; 2003 Apr; 7(2):112-9. PubMed ID: 12715337
[TBL] [Abstract][Full Text] [Related]
25. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer.
Dong Q; Kirley S; Rueda B; Zhao C; Zukerberg L; Oliva E
Mod Pathol; 2003 Sep; 16(9):863-8. PubMed ID: 13679449
[TBL] [Abstract][Full Text] [Related]
26. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
Wen YH; Yee H; Goswami S; Shukla PS
Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814
[TBL] [Abstract][Full Text] [Related]
27. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II.
Skírnisdóttir I; Seidal T; Karlsson MG; Sorbe B
Int J Oncol; 2005 Jan; 26(1):177-83. PubMed ID: 15586238
[TBL] [Abstract][Full Text] [Related]
28. Precursors of endometrial clear cell carcinoma.
Fadare O; Liang SX; Ulukus EC; Chambers SK; Zheng W
Am J Surg Pathol; 2006 Dec; 30(12):1519-30. PubMed ID: 17122507
[TBL] [Abstract][Full Text] [Related]
29. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F
Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
[TBL] [Abstract][Full Text] [Related]
31. Hepatocyte nuclear factor-1β is not a specific marker of clear cell carcinoma in serous effusions.
Davidson B
Cancer Cytopathol; 2014 Feb; 122(2):153-8. PubMed ID: 24115587
[TBL] [Abstract][Full Text] [Related]
32. Cyclooxygenase 2 expression in serous tumors of the ovary.
Singhal PK; Spiegel G; Driscoll D; Odunsi K; Lele S; Rodabaugh KJ
Int J Gynecol Pathol; 2005 Jan; 24(1):62-6. PubMed ID: 15626918
[TBL] [Abstract][Full Text] [Related]
33. SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma.
Cao D; Guo S; Allan RW; Molberg KH; Peng Y
Am J Surg Pathol; 2009 Jun; 33(6):894-904. PubMed ID: 19295406
[TBL] [Abstract][Full Text] [Related]
34. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
35. Synchronous ovarian granulosa cell tumor and uterine serous carcinoma: a rare association of a high-risk endometrial cancer with anestrogenic ovarian tumor.
Rabban JT; Gupta D; Zaloudek CJ; Chen LM
Gynecol Oncol; 2006 Dec; 103(3):1164-8. PubMed ID: 17034837
[TBL] [Abstract][Full Text] [Related]
36. The lung-restricted marker napsin A is highly expressed in clear cell carcinomas of the ovary.
Kandalaft PL; Gown AM; Isacson C
Am J Clin Pathol; 2014 Dec; 142(6):830-6. PubMed ID: 25389337
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of alternative and traditional immunohistochemical markers for the distinction of ovarian sertoli cell tumor from endometrioid tumors and carcinoid tumor: A study of 160 cases.
Zhao C; Bratthauer GL; Barner R; Vang R
Am J Surg Pathol; 2007 Feb; 31(2):255-66. PubMed ID: 17255771
[TBL] [Abstract][Full Text] [Related]
38. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
39. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
Young RH
Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic oophorectomy: a morphologic and immunohistochemical study.
Schlosshauer PW; Cohen CJ; Penault-Llorca F; Miranda CR; Bignon YJ; Dauplat J; Deligdisch L
Cancer; 2003 Dec; 98(12):2599-606. PubMed ID: 14669279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
